These investments and expenditures will enable the Singapore facility to offer complete end-to-end manufacturing, test, and supply chain management, equipped with automated systems. The company will also add 30,000 square feet within its existing facility and create approximately 100 new jobs in R&D, advanced manufacturing, service and sales over the next five years.
“Singapore is a strategic location for Agilent,” said Mike McMullen, Agilent president and CEO. “We appreciate the environment of innovation Singapore has created, as well as the important investments it is making in growing areas such as medical technology and biopharma.”
The expansion of Agilent’s manufacturing facility is a testament to Singapore’s leadership position in the medical technology field,” said Yeoh Keat Chuan, managing director, Singapore Economic Development Board. “Agilent will deepen its research capabilities and increase the value of its products and its manufacturing output through the design and development of new instruments and solutions for global markets. This is an excellent example of how leading life science tools companies look to Singapore as a home base in Asia for manufacturing, commercial functions, as well as R&D to support their future growth,” he said.
“The expansion will leverage advanced manufacturing systems and automated production technologies to support the production of a broader range of high-end analytical instruments, especially our mass-spec (mass spectrometry) products,” said Chow Woai Sheng, vice president and country general manager of Agilent Singapore.